INTRODUCTION
Weight loss is common in Parkinson's disease, particularly in the later states [l] , although its cause has been little studied. An increase in energy expenditure could contribute to this weight loss. That increased energy expenditure may be important is suggested by our clinical observation that individuals with Parkinson's disease may remain thin despite dietary supplementation resulting in a calorific intake within the normal range [l] . Energy expenditure might be raised owing to an inherent metabolic abnormality resulting in a raised resting metabolic rate, or secondary to the involuntary movements and the increased muscle rigidity which occur in the disease. In the 1920s Froment & Corajod [a] noted that metabolic rate was raised in patients with Parkinson's disease and found that treatment with hyoscine reduced the rate towards normal. They suggested that a raised metabolic rate was an intrinsic feature of the disease and used the effectiveness of different preparations of hyoscine in reducing metabolic rate as a method of assessing their effectiveness in treating the disease. However, few details of the technique used are given in their paper and few details of the patients studied were recorded; in particular there was no allowance made for the differing weights, heights and body compositions of the different groups, and in the Parkinsonian group these parameters would be expected to differ from those in the control subjects. This aspect of the disease appears to have received no further attention until a recent study, using indirect calorimetry, demonstrated that elderly patients with Parkinson's disease have raised energy expenditure [3] . The patients studied exhibited a number of different clinical patterns of Parkinson's disease, and in some involuntary movements including tremors, dystonias and dyskinetic movements, present at the time of the study, may have contributed to the raised energy expenditure seen. In addition, muscle rigidity, which occurs particularly in the untreated state and responds well to treatment with dopaminergic drugs, might result in a rise in energy expenditure. Therefore we have measured resting energy expenditure in a group of patients with Parkinson's disease who were able to lie still without exhibiting any involuntary movements. The patients were studied both on no treatment and after treatment with the dopamine agonist apomorphine, which owing to its rapid but short duration agonist apomorphine, administered subcutaneously, were studied. On the test _day, all patients' antiParkinsonian medication, except apomorphine, was omitted. This was to prevent delayed effects of oral dopaminergic drugs, which can last for a number of hours. The patients would have been unable to survive on no medication alone and therefore they were maintained on intermittent apomorphine by subcutaneous injection. Two hours before measurements were made apomorphine was also stopped. Two hours is about four times the clinical duration of a single injection of apomorphine. The use of apomorphine with its short half-life and short duration of clinical effect allowed measurements in both the treated and untreated states on the same occasion. All patients studied had a good clinical response to apomorphine and were able to lie still on a bed with no involuntary movements in both the treated and untreated states. Owing to the difficulty in studying disabled out-patients in the early morning, measurements were performed between 12.00 and 14.00 hours, 5 h after a light breakfast, after which patients consumed no food or drink except water.
Energy expenditure was measured by indirect calorimetry. Using the ventilated hood method, subjects lay on a bed with their head and shoulders within the hood; the method used was a modification of that previously described by Buchdahl et al. [S] . Room air was gently sucked from the hood via a MKS mass flow transducer. A sample of this air was dried using calcium chloride and passed to a paramagnetic oxygen analyser (540; Servomex) and an i.r. carbon dioxide analyser (Analytical Development Company). The effect of changes in barometric pressure on the gas analysers was compensated using a barometric pressure transducer (D-601; Ancom). Temperature and humidity (CH15 probe; Ancom) were used to correct ventilation flow to dry standard temperature and pressure. The voltages from the various transducers were monitored by a voltmeter (Solartron 7062), which relayed the information to a IBM-compatible computer. After correcting the variables to standard conditions, energy expenditure was calculated using the formulae of Weir [6] .
Plateau periods of approximately 10 min were used to determine energy expenditure levels. Energy expenditure was measured in both the untreated state and the treated state after a subcutaneous injection of apomorphine of between 2 and 7mg, the dose depending on the patient's usual requirements. During this time patients were watched to ensure that no involuntary movements occurred. In both states the patients' limbs were examined and muscle rigidity was scored on a scale of 0 (=absent) to 3 (=severe) in each limb, giving a total rigidity score from 0 to 12. For each patient, a rigidity change score was calculated by subtracting the total rigidity score in the treated state from that in the untreated state. Half of the patients were examined in the untreated state first and the other half in the treated state first. To assess reproducibility, the measurements were repeated twice in three patients. In three patients with dosedependent dyskinetic involuntary movements (movements appearing only on higher doses of apomorphine, greater than the dose required to produce a clinical effect on rigidity) the study was repeated with a higher dose of apomorphine and the mean energy expenditure was recorded during a 10min period when dyskinetic involuntary movements were exhibited.
Age-and sex-matched normal control subjects (hospital staff) were studied. They also fasted after a light breakfast and were also studied 5 h later between 12.00 and 14.00 hours.
The study was approved by the ethical committee of the University College and Middlesex Hospital School of Medicine.
Comparisons between Parkinsonian patients and normal subjects, and between Parkinsonian patients in the treated and untreated states, were made by Student's t-test. Correlations between the change in energy expenditure and the rigidity change score were made using Kendall's rank correlation coefficient.
RESULTS
Twelve patients with Parkinson's disease were studied. Eight were male and four were female. Their mean ( f SD) age was 58.0 ( f 9.9) years. The Hoehn & Yahr [7] stage was 3 in seven subjects and 4 in five subjects. The mean (k SD) duration of disease from diagnosis was 14.8 ( & 5.6) years. Eight healthy control subjects, recruited from hospital staff, were also studied, of whom five were male. Their mean ( f SD) age was 55.0 ( f 5.7) years.
Body weight was significantly lower in the patients with Parkinson's disease than in the control subjects: mean ( f SD) 63.0 ( k 7.8) kg compared with 73.6 (k 10.1) kg (P<O.Ol). Body mass index was also significantly lower in the group with Parkinson's disease: mean ( f SD) 21.6 ( k 3.1) kg/m2 compared with 24.4 ( f 2.3) kg/m2 ( P <0.05).
Resting energy expenditure was measured in all patients with Parkinson's disease in the untreated state. In one patient, occasional dyskinetic movements occurred throughout the treated period and therefore data from only 11 patients in the treated period were included in the analysis. The results for the individual patients with Parkinson's disease are shown in Table 1 . Resting energy expenditure was expressed as Jmin-lkg-l body weight and also as Jmin-I kg-' lean body weight. For the latter lean body mass was calculated from the body mass index using a previously validated equation [S] . Mean resting energy expenditure in both control subjects and in patients with Parkinson's disease, in both the treated and untreated states, is shown in Table 2 . In comparison with the control subjects ( resting energy expenditure expressed per kg lean body mass was significantly raised in the Parkinsonian patients both in the treated state (by 21.8%; Px0.01) and in the untreated state (by 50.8%;
Within the group of patients with Parkinson's disease resting energy expenditure expressed per kg lean body mass was higher in the untreated state than in the treated state (by 23.8%, not significant). However, when the 11 patients in whom resting energy expenditure was measured in both the treated and untreated states were examined individually, it was noted that in four patients resting energy expenditure was markedly raised in the untreated state (mean 71.0%; range 23.3-140.0%), whereas in seven subjects there was little difference between the two states. This is illustrated in Fig. 1 .
I "
T UT T UT
Fig. 1. Differences in resting energy expenditure in the treated (T) and untreated (UT) states in I1 patients with Parkinson's disease
A significant correlation was found between rigidity change score and percentage change in resting energy expenditure occurring in the untreated compared with the treated state ( P < 0.05; Kendall's rank correlation coefficient). Only in those patients who developed marked rigidity in the untreated state was resting energy expenditure significantly higher in the untreated state (Fig. 2) . A tracing from an individual patient (patient no. 7) is shown in Fig. 3 It illustrates that there was little change in resting energy expenditure when the individual initially felt that the effect of this treatment was wearing off; at a time when the rigidity score was 4, resting energy expenditure was about 10% higher than in the treated state. After a further 20min the resting energy expenditure markedly increased and at this time the rigidity score was 12. After administration of apomorphine, a total of 4mg being required, the patient noted a clinical benefit and entered a treated phase, resting energy expenditure fell, and the rigidity score fell to zero.
Resting energy expenditure in the Parkinsonian patients was also compared with predicted values obtained from the FAO/WHO/UNU age-and sexspecific equations [9] . The values, was raised by a mean of 8.6% (SD 11.2%, range -6.5 to 27.4%) in the treated state and by a mean of 34.7% (SD 53.0%, range -7.6 to 162.1%) in the untreated state. These changes are less marked than those obtained by direct comparison with our control group. However, when compared with their resting energy expenditure predicted from these equations, our control subjects had a resting energy expenditure that was reduced by a mean of -5.8% (SD 11.6, range -21.0 to 14.8%). This is consistent with our previous experience that the FAO/WHO/ UNU equations produce values of resting energy expenditure that are higher than our control values. In three patients (patient nos. 1, 4 and lo), who were known to experience peak dose dyskinetic movements, resting energy expenditure measurements were repeated after higher doses of apomorphine and all exhibited dyskinetic movements while lying on the bed. Resting energy expenditure, compared with the preceeding untreated state, was increased by 25.4%, 15.37% and 129.58% in the three patients (Table 3) .
In three patients (patient nos. 1, 3 and 12) resting energy expenditure was measured during two untreated states, separated by a period of treatment with apomorphine, to assess reproducibility. The mean variation was 3.1% (7.7%, 1.35% and -0.3% in the individual patients).
DISCUSSION
These results confirm that resting energy expenditure is increased in Parkinson's disease in both the untreated state and after treatment with the dopamine agonist apomorphine. Owing to the use of disabled out-patients, it was not possible to measure early morning energy expenditure after an overnight fast. However, the results using our protocol are likely to be good approximations to basal metabolic rate because our values of energy expenditure in control subjects were no greater than those that we have measured previously in control subjects after an overnight fast.
This increase in resting energy expenditure is seen in the absence of any involuntary movements. We found that the resting energy expenditure was simi-lar in both the treated and untreated states in the majority of patients. However, a minority of patients showed markedly higher energy expenditure in the untreated state compared with the treated state, and the difference was as high as 140% in one patient. This difference was only noted in those patients who developed marked muscle rigidity in the untreated state. The results suggest that the rigidity is responsible for the rise in energy expenditure, although a rise might be seen secondary to the neuroendocrine responses to discomfort caused by the extreme rigidity. Against this explanation is the fact that no rise in pulse rate was seen during these 'rigid' untreated phases, and also that two patients who had markedly increased energy expenditure in the untreated state did not experience pain at the time.
This markedly increased resting energy expenditure seen in some patients, and associated with rigidity, suggests that muscle rigidity may be an important cause of raised energy expenditure, and also of weight loss, in Parkinson's disease. During the day such severe rigidity can often be prevented by treatment, but it may be particularly important at night, as L-dopa has too short a half-life to continue to act throughout the night.
However, our results also showed that in the treated state when rigidity is markedly reduced, and in those patients in whom only minimal rigidity was present, resting energy expenditure was still raised compared with control subjects. Recently, Brouselle et al.
[lo] have shown a similar increase in energy expenditure in Parkinson's disease, again of about 30%. Like us, they found a similar increase over control subjects in both treated and untreated patients. In addition, they found that this elevation was also present in patients with early untreated disease. This suggests that a raised resting energy expenditure is an integral part of Parkinson's disease in many patients. A possible cause of this might be a neuroendocrine disturbance. Since hypothalamic dopamine plays an important role in the hypothalamo-pituitary axis, a disturbance of the thyrotropin-releasing hormone (TRH)-thyrotropin (thyroid-stimulating hormone, TSH) axis might exist. Evidence against this being important is that normal thyroid function tests, including TSH [lo] gave the P-adrenoceptor blocker pindolol to six Parkinsonian patients and showed a modest reduction in energy expenditure, from 30% to 21% above control values [lo] . However, pindolol has some intrinsic sympathomimetic activity, making interpretation of the results difficult. Therefore it is possible that sympathetic overactivity may play a role in the raised energy expenditure seen in Parkinson's disease.
Our results are the first to demonstrate the additional increase in energy expenditure seen in the dyskinetic state. These are even more striking in view of the fact that at the time of measurement all patients were lying on a bed and at rest dyskinetic movements tend to be reduced, while during normal daily activity their dyskinetic movements are much more severe. The degree of energy expenditure elevation seen during normal daily activities is therefore likely to be an important factor in the weight loss associated with Parkinson's disease; this fits with evidence from an anthropometric study in which the presence of severe dyskinesias was found to correlate most closely with reduced body mass index [l].
